Stockreport

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF TROPION-Lung01, evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free surv [Read more]